Biotechnology

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

The latest astronaut crew on the ISS is conducting cutting-edge research in microgravity, aiming to revolutionize healthcare and environmental tech on Earth.

A new patent-pending AI platform from Montreal's E-Biotech promises to streamline GMP compliance by integrating with, not replacing, existing systems.

AVEO Oncology's ficlatuzumab advances in a pivotal Phase 3 trial, offering new hope for patients with a difficult-to-treat form of head and neck cancer.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

Unnatural Products inks a major deal with Novartis, using its AI-driven macrocycle technology to develop novel cardiovascular drugs for intractable diseases.

The research giant took a massive Q4 loss from asset impairments but points to improving client demand and a strategic overhaul as signs of a turnaround.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

Positive early trial data for ZP9830 shows promise for a new class of targeted autoimmune therapies, marking a strategic pivot for Zealand Pharma.

A new hair-root innovation from Thai universities uses Riceberry rice to fight hair loss at the cellular level, boosting local farmers and global markets.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

Primex Inc. hires a life sciences expert to drive its OneVue Sense solution deeper into the critical and highly regulated healthcare and biopharma markets.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

The largest study of its kind reveals metabolic signatures that predict severe neurotoxicity in CAR T-cell patients, paving the way for safer treatments.

The American Diabetes Association is funding seven visionary scientists using AI, CRISPR, and stem cells to forge the next frontier in diabetes treatment.

Sanofi promotes Dupixent growth driver Manuela Buxo to lead its crucial Specialty Care unit, ensuring continuity as competition and a new AI focus intensify.